罗欣药业:2024年报净利润-9.65亿 同比下降45.99%

Financial Performance - The company reported a basic earnings per share of -0.9100 yuan for 2024, a decrease of 49.18% compared to -0.6100 yuan in 2023 [1] - The net profit for 2024 was -9.65 billion yuan, representing a 45.99% increase in losses from -6.61 billion yuan in 2023 [1] - The total revenue for 2024 was 26.47 billion yuan, an increase of 11.97% from 23.64 billion yuan in 2023 [1] - The return on equity for 2024 was -50.63%, a significant decline from -23.42% in 2023 [1] - The net asset per share decreased to 1.27 yuan, down 44.05% from 2.27 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 56,265.79 million shares, accounting for 51.82% of the circulating shares, with a decrease of 3,099.52 million shares compared to the previous period [2] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., holds 23,695.55 million shares, representing 21.82% of the total share capital, with no change [3] - The second-largest shareholder, Fang Xiubao, holds 10,029.43 million shares, accounting for 9.24% of the total share capital, also unchanged [3] - Notably, Chen Laiyang reduced his holdings by 1,570.00 million shares, while Zhang Bin decreased his holdings by 1,715.00 million shares [3] Dividend Policy - The company has decided not to distribute dividends or increase capital [2]